TECH News and Press, Bio-Techne Corp

2024-06-20 21:56:16 ET Summary Baron Capital's 13F stock portfolio value decreased slightly this quarter to $37.52B. Top five stakes include Tesla Motors, Gartner Inc, Arch Capital Group, CoStar Group, and MSCI Inc, totaling ~27% of the portfolio. Stake increases in Red Rock R...

BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES PR Newswire MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer will present at the following invest...

BIO-TECHNE TO HIGHLIGHT MULTIPLE APPLICATIONS OF THE MauriceFlex™ SYSTEM AT THE ANNUAL ASMS CONFERENCE PR Newswire MINNEAPOLIS , May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched Maurice...

ScaleReady Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing PR Newswire ST. PAUL, Minn. , May 29, 2024 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio...

2024-05-28 18:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-26 12:20:00 ET Summary Conestoga Capital Advisors LLC is a boutique, independent investment advisory firm specializing in the management of Micro, Small, SMid and Mid Cap Growth equities. Conestoga Capital Advisors utilizes a fundamental, bottom-up research process and employs...

BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE PR Newswire MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman , President and Chief Executive Officer wi...

2024-05-22 14:32:33 ET More on Bio-Techne Bio-Techne Corporation (TECH) Q3 2024 Earnings Call Transcript Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence Bio-Techne Non-GAAP EPS of $0.48 beats by $0.02, revenue of $303.4M beats by $10.7M ...

BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY PR Newswire MINNEAPOLIS , May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a b...

2024-05-20 13:34:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn’t mean much if...